You have probably seen the adds. With Keytruda there is a chance to live longer. But how much longer?
Among patients whose PD-L1 levels were from 1% to 19%, those who got Keytruda lived for a median of 16.7 months after diagnoses while those who got chemotherapy lived a median of 12.8 months.
Among patients with PD-L1 levels from 20% to 49%, those who got Keytruda lived a median of 17.7 months compared with 13 months for patients on chemotherapy.
Patients whose PD-L1 levels were above 50% — those for whom Keytruda already has the FDA’s blessing — survived a median of 20 months with Keytruda, compared with 12.2 months for chemotherapy.
NOTE: Numbers vary by the type of cancer being treated, some are longer than above.
The cost of Keytruda for one year is $150,000. Is living four to eight months longer worth $150,000? If you are the patient no doubt it is.